Evaluation of the efficacy of gemfibrozil as an adjunct therapy in improving the symptoms of major depressive disorder

Evaluation of the efficacy of gemfibrozil as an adjunct therapy in improving the symptoms of major depressive disorder; A double- blind, placebo-controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N119

Enrollment

Registered

2019-03-17

Start date

2019-04-05

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder. Major depressive disorder, single episode, severe without psychotic features

Interventions

Intervention 1: Intervention group: tablet sertralin 100 mg/day plus Capsule gemfibrozil 300 mg per day as intervention group for 8 weeks. Intervention 2: Control group: tablet sertralin 100 mg/day p

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Presence of Major Depressive Disorder based on DSM-5 criteria Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 22 Age between 18 to 60 years

Exclusion criteria

Exclusion criteria: Presence of psychosis Substanse use disorder except for nicotine and caffeine IQ lower than 70 Any other mental disorder Any significant neurologic or medical disease(advanced renal disease, CKD, hepatic disease, cardiovascular disease) history of cholelithiasis Receiving Warfarin Recieving Insulin Receiving statins Receiving niacin

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Baseline and weeks 2,4 and 8. Method of measurement: by Hamiltion Depression Rating Scale 17-Item.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026